

Disclosure

This study received funding from Gilead Sciences, Roche Laboratories, and Hepatitis B Foundation (Investigator Sponsored Research)

0991 - THE BURDEN OF & BARRIERS TO CARE FOR HEPATITIS C VIRUS (HCV) IN HO CHI MINH CITY, VIETNAM: A COMPREHENSIVE POPULATION-BASED PREVALENCE STUDY

Trang Ngoc Doan Pham^{1,2}, Diem Vu Bich Dao¹, Loc Phan¹, Dung Ngo³, Anh Ngoc Le¹, William M Lee^{1,4}, Amy Trang¹, Gary Mize¹, Robert G Gish^{1,5}, Moon Chen Jr^{1,6}, Hai Thanh Phan⁷, Binh Tan Nguyen⁸, Hong Kim Tang³, and Doan Y Dao^{1,9}

- 1. Vietnam Viral Hepatitis Alliance
- 2. The University of Illinois at Chicago School of Public Health
- 3. Pham Ngoc Thach University of Medicine

- 4. University of Texas Southwestern Medical Center-Division of Digestive and Liver Disease
- 5. Loma Linda University 6. University of California at Davis

- 7. Medic Medical Center
- 8. Ho Chi Minh City Department of Health
- 9. Johns Hopkins School of Medicine

Background

- The true HCV prevalence in Ho Chi Minh City (HCMC) is unknown
- We conducted a prevalence study of HCV and identified the barriers to full care for HCV in HCMC.

Method

- Data from Probability Proportionate to Size sampling studies conducted in HCMC from 2016 – 2020:
- 19,400 representative adults (18+) were invited to free screening to identify HCV statuses and access to care
- Selected characteristics of participants were obtained: demographics, risk factors (blood transfusions, tattoo, drug abuse, needle sharing, condom use, at least a family member with HBV or HCV) and waist circumference (cutoff 90cm for men, 80cm for women)
- Written health education and care referral information were provided in combination with results. Persons with antiHCV+ or "gray zone" were further tested for quantitative HCV RNA and referred to hepatologist according to viral load results.
- Multinomial logistic regression with backward selection were used to model the unweighted association of participants characteristics and HCV statuses (antiHCV Ab) at $\alpha = 0.05$

Results

- 97% of 15,094 respondents were screened and had complete data. 2/3 were women
- Median age 52 years old (IQR) = 21), ranging from 18-94


Among the antiHCV+ individuals

- 69% had concurrent antiHBcT +, of whom 5.6% also had HBsAg+
- 91.6% had low-middle income (<\$340 USD/month)
- 71/1% had less than high school education
- 55.7% had central obesity

After adjusted for demographics and risk factors, the odds of antiHCV+ was significant higher in male, age 60+, had history of drug abuse, tattoo and blood transfusion.

Linkage to care referral - As of June 2020

- •The program successful contacted and linked 173 (44.2%) patients to viral load testing.
- Among those who followed-up:
- 91% were insured
- 92% received health education and care referral information
- 61% got consultation from hepatologists
- Of those who followed up, 31% used insurance to pay for HCV management



Conclusion

- The burden of HCV is considerable in HCMC.
- About 2/3 of HCV patients have concurrent anti-HBc total (+) suggesting that close monitoring for HBV reactivation during HCV treatment may be warranted.
- HCV disproportionately afflicts older adult males (60+), low socioeconomic status, with high-risk backgrounds.
- HCV patients were motivated to seek medical care, yet the low insurance usage remains to be addressed.